Harvard Bioscience, Inc.

NasdaqGM:HBIO Rapporto sulle azioni

Cap. di mercato: US$94.2m

Harvard Bioscience Crescita futura

Future criteri di controllo 3/6

Harvard Bioscience prevede che gli utili e i ricavi cresceranno rispettivamente di 82.2% e 5.8% all'anno. Si prevede che l'EPS crescerà di 82.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 1.3% in 3 anni.

Informazioni chiave

82.2%

Tasso di crescita degli utili

82.5%

Tasso di crescita dell'EPS

Life Sciences crescita degli utili18.3%
Tasso di crescita dei ricavi5.8%
Rendimento futuro del capitale proprio1.3%
Copertura analitica

Low

Ultimo aggiornamento08 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Nov 07
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08
Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01
Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19
These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04
Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20
Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07
What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17
Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:HBIO - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026112211141
12/31/202598-6572
12/31/202494-14-122
9/30/202498-1404N/A
6/30/2024101-1169N/A
3/31/2024107-91114N/A
12/31/2023112-31214N/A
9/30/2023113-31112N/A
6/30/2023114-579N/A
3/31/2023115-245N/A
12/31/2022113-1001N/A
9/30/2022118-7-3-1N/A
6/30/2022121-4-4-3N/A
3/31/2022121-6-3-2N/A
12/31/2021119001N/A
9/30/2021117-224N/A
6/30/2021111-356N/A
3/31/2021105-467N/A
12/31/2020102-889N/A
9/30/2020102-789N/A
6/30/2020105-8911N/A
3/31/2020112-789N/A
12/31/2019116-578N/A
9/30/2019119-288N/A
6/30/2019120034N/A
3/31/2019122-144N/A
12/31/2018121-423N/A
9/30/2018109-8-2-1N/A
6/30/201899-8N/A3N/A
3/31/201886-7N/A2N/A
12/31/201777-2N/A1N/A
9/30/201782-3N/A4N/A
6/30/201788-4N/A5N/A
3/31/201796-4N/A5N/A
12/31/2016105-4N/A5N/A
9/30/2016106-20N/A5N/A
6/30/2016107-19N/A2N/A
3/31/2016110-18N/A0N/A
12/31/2015109-19N/A1N/A
9/30/2015111-2N/A0N/A
6/30/20151100N/A1N/A
3/31/20151090N/A3N/A
12/31/20141092N/A4N/A
9/30/20141062N/A4N/A
6/30/20141061N/A5N/A
3/31/20141051N/A5N/A
12/31/20131051N/A4N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che HBIO diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che HBIO diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede HBIO diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di HBIO ( 5.8% all'anno) crescerà più lentamente rispetto al mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di HBIO ( 5.8% all'anno) crescerà più lentamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di HBIO sarà basso tra 3 anni ( 1.3 %).


Scoprire le aziende in crescita